<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>From Cells to Circuits | Protecting Cognitive Function in GBM Care</title>
    <style>
        * {
            margin: 0;
            padding: 0;
            box-sizing: border-box;
        }

        :root {
            --primary-white: #FFFFFF;
            --charcoal: #2C3E50;
            --slate-blue: #5D7A99;
            --soft-gray-blue: #E8EDF2;
            --text-dark: #3A3A3A;
            --border-light: #E8EDF2;
        }

        body {
            font-family: 'Inter', 'Neue Haas Grotesk', -apple-system, BlinkMacSystemFont, 'Segoe UI', sans-serif;
            color: var(--text-dark);
            line-height: 1.7;
            font-size: 18px;
        }

        /* Navigation */
        nav {
            position: fixed;
            top: 0;
            width: 100%;
            background: var(--primary-white);
            box-shadow: 0 2px 10px rgba(0,0,0,0.05);
            z-index: 1000;
            padding: 1.5rem 0;
        }

        .nav-container {
            max-width: 1400px;
            margin: 0 auto;
            padding: 0 3rem;
            display: flex;
            justify-content: space-between;
            align-items: center;
        }

        .logo {
            font-size: 1.2rem;
            font-weight: 600;
            color: var(--charcoal);
            text-decoration: none;
            letter-spacing: -0.5px;
        }

        .nav-links {
            display: flex;
            list-style: none;
            gap: 2.5rem;
        }

        .nav-links a {
            color: var(--text-dark);
            text-decoration: none;
            font-size: 0.95rem;
            font-weight: 400;
            transition: color 0.3s;
        }

        .nav-links a:hover {
            color: var(--slate-blue);
        }

        /* Hero Section */
        .hero {
            margin-top: 80px;
            background: linear-gradient(180deg, var(--primary-white) 0%, var(--soft-gray-blue) 100%);
            padding: 150px 3rem;
            text-align: center;
        }

        .hero h1 {
            font-size: 3.5rem;
            font-weight: 300;
            color: var(--charcoal);
            margin-bottom: 1.5rem;
            letter-spacing: -1px;
        }

        .hero h2 {
            font-size: 1.5rem;
            font-weight: 400;
            color: var(--slate-blue);
            margin-bottom: 2rem;
            max-width: 900px;
            margin-left: auto;
            margin-right: auto;
        }

        .mission-statement {
            font-size: 1.2rem;
            max-width: 800px;
            margin: 3rem auto 3rem;
            color: var(--text-dark);
            line-height: 1.8;
        }

        .cta-button {
            display: inline-block;
            background: var(--slate-blue);
            color: var(--primary-white);
            padding: 1rem 3rem;
            text-decoration: none;
            border-radius: 2px;
            font-size: 1rem;
            transition: background 0.3s;
            margin-top: 2rem;
        }

        .cta-button:hover {
            background: var(--charcoal);
        }

        /* Container */
        .container {
            max-width: 1200px;
            margin: 0 auto;
            padding: 100px 3rem;
        }

        .section {
            padding: 100px 0;
        }

        .section-title {
            font-size: 2.5rem;
            font-weight: 300;
            color: var(--charcoal);
            margin-bottom: 3rem;
            text-align: center;
            letter-spacing: -0.5px;
        }

        .section-subtitle {
            font-size: 1.3rem;
            font-weight: 400;
            color: var(--slate-blue);
            margin-bottom: 2rem;
            text-align: center;
        }

        /* Image Styles */
        .content-image {
            max-width: 100%;
            height: auto;
            margin: 2rem 0;
            border-radius: 4px;
            box-shadow: 0 4px 15px rgba(0,0,0,0.1);
        }

        .image-caption {
            font-size: 0.9rem;
            color: var(--slate-blue);
            font-style: italic;
            margin-top: 0.5rem;
            text-align: center;
        }

        .two-column-image {
            display: grid;
            grid-template-columns: 1fr 1fr;
            gap: 2rem;
            margin: 3rem 0;
        }

        /* Three Column Explainer */
        .three-column {
            display: grid;
            grid-template-columns: repeat(3, 1fr);
            gap: 3rem;
            margin: 5rem 0;
        }

        .column {
            padding: 2.5rem;
            border: 1px solid var(--border-light);
            background: var(--primary-white);
        }

        .column h3 {
            font-size: 1.5rem;
            font-weight: 500;
            color: var(--charcoal);
            margin-bottom: 1.5rem;
        }

        .column p {
            color: var(--text-dark);
            line-height: 1.8;
        }

        /* Stats Section */
        .stats {
            background: var(--slate-blue);
            color: var(--primary-white);
            padding: 100px 3rem;
            text-align: center;
        }

        .stats h2 {
            font-size: 5rem;
            font-weight: 300;
            margin-bottom: 1rem;
        }

        .stats h3 {
            font-size: 1.8rem;
            font-weight: 400;
            margin-bottom: 2rem;
        }

        .stats p {
            font-size: 1.1rem;
            max-width: 800px;
            margin: 0 auto;
            line-height: 1.8;
        }

        /* Content Sections */
        .content-section {
            margin-bottom: 4rem;
        }

        .content-section h3 {
            font-size: 1.8rem;
            font-weight: 400;
            color: var(--charcoal);
            margin-bottom: 1.5rem;
            margin-top: 3rem;
        }

        .content-section h4 {
            font-size: 1.3rem;
            font-weight: 500;
            color: var(--slate-blue);
            margin-bottom: 1rem;
            margin-top: 2rem;
        }

        .content-section p {
            margin-bottom: 1.5rem;
            line-height: 1.8;
        }

        .content-section ul, .content-section ol {
            margin-left: 2rem;
            margin-bottom: 1.5rem;
        }

        .content-section li {
            margin-bottom: 0.8rem;
            line-height: 1.8;
        }

        /* Call to Action Strip */
        .cta-strip {
            background: var(--charcoal);
            color: var(--primary-white);
            padding: 80px 3rem;
            text-align: center;
        }

        .cta-strip h3 {
            font-size: 1.8rem;
            font-weight: 400;
            margin-bottom: 2rem;
        }

        .cta-buttons {
            display: flex;
            gap: 2rem;
            justify-content: center;
            margin-top: 2rem;
        }

        .cta-strip .cta-button {
            background: var(--primary-white);
            color: var(--charcoal);
        }

        .cta-strip .cta-button:hover {
            background: var(--soft-gray-blue);
        }

        /* Evidence Box */
        .evidence-box {
            background: var(--soft-gray-blue);
            padding: 3rem;
            margin: 3rem 0;
            border-left: 4px solid var(--slate-blue);
        }

        .evidence-box h4 {
            color: var(--charcoal);
            margin-bottom: 1rem;
        }

        /* Questions Box */
        .questions-box {
            background: var(--primary-white);
            border: 2px solid var(--slate-blue);
            padding: 3rem;
            margin: 3rem 0;
        }

        .questions-box h4 {
            color: var(--charcoal);
            margin-bottom: 1.5rem;
        }

        /* Footer */
        footer {
            background: var(--charcoal);
            color: var(--primary-white);
            padding: 80px 3rem 40px;
        }

        .footer-content {
            max-width: 1200px;
            margin: 0 auto;
            display: grid;
            grid-template-columns: repeat(3, 1fr);
            gap: 4rem;
            margin-bottom: 3rem;
        }

        .footer-section h4 {
            font-size: 1.2rem;
            font-weight: 500;
            margin-bottom: 1.5rem;
        }

        .footer-section p, .footer-section a {
            color: rgba(255,255,255,0.8);
            line-height: 1.8;
            text-decoration: none;
            display: block;
            margin-bottom: 0.8rem;
            font-size: 0.95rem;
        }

        .footer-section a:hover {
            color: var(--primary-white);
        }

        .footer-bottom {
            max-width: 1200px;
            margin: 0 auto;
            padding-top: 3rem;
            border-top: 1px solid rgba(255,255,255,0.1);
            text-align: center;
            color: rgba(255,255,255,0.6);
            font-size: 0.9rem;
        }

        /* References Section in Footer */
        .references-section {
            max-width: 1200px;
            margin: 3rem auto 0;
            padding-top: 3rem;
            border-top: 1px solid rgba(255,255,255,0.1);
        }

        .references-section h4 {
            color: var(--primary-white);
            margin-bottom: 1.5rem;
            font-size: 1.1rem;
        }

        .references-section p {
            font-size: 0.85rem;
            line-height: 1.6;
            margin-bottom: 0.8rem;
            color: rgba(255,255,255,0.7);
        }

        /* Responsive */
        @media (max-width: 768px) {
            .three-column {
                grid-template-columns: 1fr;
                gap: 2rem;
            }

            .two-column-image {
                grid-template-columns: 1fr;
            }

            .hero h1 {
                font-size: 2.5rem;
            }

            .nav-links {
                display: none;
            }

            .footer-content {
                grid-template-columns: 1fr;
                gap: 3rem;
            }

            .cta-buttons {
                flex-direction: column;
            }

            .stats h2 {
                font-size: 3.5rem;
            }
        }

        html {
            scroll-behavior: smooth;
        }
    </style>
</head>
<body>
    <!-- Navigation -->
    <nav>
        <div class="nav-container">
            <a href="#" class="logo">From Cells to Circuits</a>
            <ul class="nav-links">
                <li><a href="#home">Home</a></li>
                <li><a href="#patients">For Patients</a></li>
                <li><a href="#clinicians">For Clinicians</a></li>
                <li><a href="#implementation">Implementation</a></li>
                <li><a href="#resources">Resources</a></li>
                <li><a href="#contact">Contact</a></li>
            </ul>
        </div>
    </nav>

    <!-- Hero Section -->
    <section id="home" class="hero">
        <h1>Protecting What Makes You, You</h1>
        <h2>Precision glioblastoma care that treats tumors while preserving memory, language, and cognitive function.</h2>
        <p class="mission-statement">Integrating patient-derived organoid testing with brain network mapping to guide safer, smarter cancer treatment.</p>
        <a href="#patients" class="cta-button">Learn How It Works</a>
    </section>

    <!-- Three Column Explainer -->
    <div class="container">
        <div class="three-column">
            <div class="column">
                <h3>What Are Organoids?</h3>
                <p>Miniature brain tissues grown from your cells that allow doctors to test which drugs work best for your specific tumor—before you receive them.</p>
            </div>
            <div class="column">
                <h3>What Is the Connectome?</h3>
                <p>A detailed map of your brain's communication networks, identifying memory and language circuits that should be protected during treatment.</p>
            </div>
            <div class="column">
                <h3>Why Combine Them?</h3>
                <p>By pairing drug-response testing with network vulnerability mapping, your care team can select treatments that maximize tumor control while minimizing cognitive impact.</p>
            </div>
        </div>
    </div>

    <!-- By the Numbers -->
    <section class="stats">
        <h2>1 in 3</h2>
        <h3>GBM patients experience significant cognitive decline from treatment</h3>
        <p>Standard protocols prioritize tumor control but rarely account for therapy-related damage to memory and language networks. Research shows that connectome disruptions in glioblastoma patients are widespread beyond focal lesions, associated with impaired cognitive function and worse survival outcomes. A new generation of precision tools changes that equation.</p>
    </section>

    <!-- Patient Section -->
    <section id="patients" class="section">
        <div class="container">
            <h2 class="section-title">Understanding Your Treatment Options</h2>
            
            <div class="content-section">
                <h3>What Is Glioblastoma?</h3>
                <p>Glioblastoma (GBM) is an aggressive brain tumor that requires urgent, intensive treatment. Standard care combines surgery, radiation, and chemotherapy. While these therapies target the tumor, they can also affect healthy brain tissue—particularly the networks responsible for memory, language, and decision-making.</p>
                <p>Until recently, there was no practical way to predict how different treatments would affect your cognitive function. That's changing.</p>
            </div>

            <div class="content-section">
                <h3>Why Protecting Cognition Matters</h3>
                
                <!-- Patient-friendly brain illustration -->
                <img src="https://images.unsplash.com/photo-1559757175-5700dde675bc?w=800" alt="Brain networks illustration" class="content-image" style="max-width: 600px; display: block; margin: 2rem auto;">
                <p class="image-caption">Your brain's networks control memory, language, and thinking. Image: Unsplash/Robina Weermeijer</p>

                <p>Your quality of life depends on more than tumor control. Preserving your ability to remember, communicate, and think clearly allows you to:</p>
                <ul>
                    <li>Maintain independence in daily activities</li>
                    <li>Continue meaningful relationships</li>
                    <li>Participate actively in treatment decisions</li>
                    <li>Plan for your future with clarity</li>
                </ul>
                <p>Research shows that treatment-related cognitive decline is often preventable when care teams have the right information at the right time.</p>
            </div>

            <div class="content-section">
                <h3>What Is Organoid Testing?</h3>
                <h4>How It Works</h4>
                <p>Think of organoids as miniature models of your tumor grown in a laboratory from your own cells. These tiny "mini-brains" allow scientists to test different drugs and see which ones work best against your specific tumor.</p>
                
                <!-- Cerebral organoid image from research -->
                <img src="https://media.springernature.com/lw685/springer-static/image/art%3A10.1038%2Fs41418-020-00679-7/MediaObjects/41418_2020_679_Fig1_HTML.png" alt="Cerebral organoid development stages" class="content-image">
                <p class="image-caption">How brain organoids develop from stem cells. Source: Nature Cell Death & Differentiation (2020)</p>

                <div class="evidence-box">
                    <h4>What This Means for You</h4>
                    <ul>
                        <li><strong>Personalized treatment:</strong> Doctors can test multiple drugs on your organoid before choosing the best one for you</li>
                        <li><strong>Avoid ineffective drugs:</strong> Skip treatments unlikely to help your specific tumor</li>
                        <li><strong>Faster decisions:</strong> Get results in weeks rather than months of trial and error</li>
                    </ul>
                </div>

                <p>Recent studies from institutions like Weill Cornell Medicine have shown that organoid models successfully predict how patients respond to treatment, making them a powerful tool for personalizing your care.</p>
            </div>

            <div class="content-section">
                <h3>What Is Connectome Mapping?</h3>
                <h4>How It Works</h4>
                <p>Your brain is like a complex highway system, with billions of connections linking different regions. Some areas act as major hubs—like central stations—coordinating memory, language, and thinking. A connectome scan creates a map showing exactly where these important hubs are located.</p>

                <!-- Brain network visualization for patients -->
                <img src="https://images.unsplash.com/photo-1559757148-5c350d0d3c56?w=800" alt="Brain connection networks" class="content-image" style="max-width: 600px; display: block; margin: 2rem auto;">
                <p class="image-caption">Brain networks visualized: white matter connections coordinate memory and language. Image: Unsplash</p>

                <p>The scan uses special MRI techniques that track how different brain regions communicate. This information helps your surgical team plan the safest approach and helps radiation oncologists avoid critical areas.</p>
                
                <div class="evidence-box">
                    <h4>What This Means for You</h4>
                    <ul>
                        <li><strong>Personalized surgical planning:</strong> Surgeons can avoid damage to your critical memory and language centers</li>
                        <li><strong>Optimized radiation:</strong> Radiation fields shaped to protect vulnerable networks</li>
                        <li><strong>Better predictions:</strong> Doctors can estimate cognitive risks before treatment starts</li>
                        <li><strong>Long-term quality of life:</strong> Reduced risk of preventable cognitive problems</li>
                    </ul>
                </div>

                <p>Research from major medical centers has demonstrated that connectome mapping can identify brain network disruptions invisible on standard MRI scans, helping predict treatment outcomes and preserve cognitive function.</p>
            </div>

            <div class="content-section">
                <h3>How These Tools Work Together</h3>
                <p><strong>Organoid testing</strong> tells your doctor which drugs will fight your tumor most effectively.</p>
                <p><strong>Connectome mapping</strong> tells your doctor which treatments pose the lowest risk to your memory and thinking abilities.</p>
                <p>Together, they form a complete picture: <strong>the right treatment for your tumor, chosen with your brain's health in mind.</strong></p>

                <img src="https://images.unsplash.com/photo-1582719471884-ba5fc51e9884?w=800" alt="Doctor reviewing brain scans" class="content-image" style="max-width: 700px; display: block; margin: 2rem auto;">
                <p class="image-caption">Doctors use advanced imaging to plan safer treatments. Image: Unsplash/National Cancer Institute</p>
            </div>

            <div class="questions-box">
                <h3>Questions to Ask Your Doctor</h3>
                
                <h4>Before Surgery:</h4>
                <ul>
                    <li>Can we order a connectome scan to map my memory and language networks?</li>
                    <li>How will the surgical approach account for cognitive-risk areas?</li>
                    <li>Which brain networks are most vulnerable in my case?</li>
                </ul>

                <h4>Before Starting Chemotherapy or Targeted Therapy:</h4>
                <ul>
                    <li>Is organoid testing available to identify which drugs my tumor is sensitive to?</li>
                    <li>Can we cross-reference drug options with my connectome map?</li>
                    <li>How long does organoid testing take?</li>
                </ul>

                <h4>During Treatment:</h4>
                <ul>
                    <li>How will my cognitive function be monitored over time?</li>
                    <li>Are there alternative therapies if my current regimen shows cognitive impact?</li>
                    <li>What early warning signs should I watch for?</li>
                </ul>

                <h4>For Clinical Trials:</h4>
                <ul>
                    <li>Does this trial incorporate organoid or connectome data?</li>
                    <li>How does the trial protocol account for cognitive outcomes?</li>
                </ul>
            </div>

            <div class="content-section">
                <h3>You Have the Right to Ask</h3>
                <p>Organoid testing and connectome mapping are evidence-based tools backed by research from institutions like Weill Cornell Medicine, Oxford University, and The Lancet Neurology. Forward-thinking cancer centers are beginning to integrate these approaches into standard care.</p>
                <p>Bringing these options to your care team's attention is not just reasonable—it's an important part of advocating for the best possible treatment.</p>
            </div>
        </div>
    </section>

    <!-- CTA Strip -->
    <section class="cta-strip">
        <h3>Ready to Learn More?</h3>
        <div class="cta-buttons">
            <a href="#patients" class="cta-button">Patient Resources</a>
            <a href="#clinicians" class="cta-button">Clinical Overview</a>
        </div>
    </section>

    <!-- Clinicians Section -->
    <section id="clinicians" class="section">
        <div class="container">
            <h2 class="section-title">Clinical Integration of Organoid Profiling & Connectome Mapping</h2>
            <p class="section-subtitle">Evidence-based tools for cognition-preserving precision neuro-oncology</p>

            <div class="content-section">
                <h3>The Clinical Challenge</h3>
                <p>Standard GBM protocols achieve modest survival gains but frequently cause significant treatment-related cognitive morbidity. Chemotherapy, radiation, and surgical corridors disrupt memory, language, and executive networks—deficits that persist long after oncologic intervention and profoundly impact quality of life.</p>
                <p>Conventional imaging cannot predict patient-specific drug sensitivity or identify which neural circuits are most vulnerable to therapy. Treatment planning remains largely tumor-centric, with cognitive outcomes addressed reactively.</p>
            </div>

            <div class="content-section">
                <h3>Organoid Drug-Response Profiling</h3>
                
                <!-- Research figure showing organoid drug testing -->
                <img src="https://www.cell.com/cms/attachment/e0c88fbc-cec8-4b49-b36d-0c9cd0c5b8d7/gr1.jpg" alt="Patient-derived glioblastoma organoids and drug response" class="content-image">
                <p class="image-caption">Patient-derived GBM organoids show heterogeneous TMZ sensitivity. Source: Cell Reports (2019) - Linkous et al., Weill Cornell Medicine</p>

                <h4>Methodology</h4>
                <p>Patient-derived organoids generated from surgical specimens or iPSCs recapitulate tumor microenvironment and cellular heterogeneity. Systematic drug-panel testing includes:</p>
                <ul>
                    <li>Standard-of-care agents: temozolomide, lomustine, carmustine</li>
                    <li>Targeted therapies: EGFR inhibitors, VEGF inhibitors, mTOR inhibitors, MEK inhibitors</li>
                    <li>Salvage regimens: bevacizumab, tumor-treating fields, immunotherapy combinations</li>
                    <li>Novel compounds: identified through high-throughput screening</li>
                </ul>

                <h4>Assays Performed</h4>
                <ul>
                    <li>Viability assays (ATP, alamarBlue, live/dead staining)</li>
                    <li>Apoptosis markers (caspase-3, TUNEL, AO/PI staining)</li>
                    <li>Proliferation indices (Ki67, EdU incorporation)</li>
                    <li>Pathway activation (phospho-proteomics, Western blot)</li>
                    <li>Molecular profiling (MGMT, IDH, EGFR, PTEN, TP53)</li>
                </ul>

                <div class="evidence-box">
                    <h4>Clinical Utility - Key Research Findings</h4>
                    <p><strong>Organoid assays reveal actionable heterogeneity beyond molecular profiling:</strong></p>
                    <ul>
                        <li>TMZ sensitivity does not consistently correlate with MGMT methylation status in organoid models, highlighting importance of functional testing</li>
                        <li>GBM organoids preserve patient-specific drug response patterns and maintain tumor heterogeneity across passages</li>
                        <li>Organoid drug screening enables identification of effective salvage therapies in treatment-resistant cases</li>
                        <li>High-throughput organoid screening allows simultaneous testing of combination therapies</li>
                    </ul>
                    <p><em>Sources: npj Precision Oncology (2024), Nature Communications (2025), Cell Reports (2019), PMC publications</em></p>
                </div>
            </div>

            <div class="content-section">
                <h3>Connectome-Based Vulnerability Mapping</h3>
                
                <!-- Connectome tractography visualization -->
                <div class="two-column-image">
                    <div>
                        <img src="https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/brain/146/4/10.1093_brain_awac360/1/m_awac360f1.jpeg?Expires=1738369889&Signature=Pt8OP5b2i5A6-TU~4k5d6~DFxPSB-mKw7GXhqM5yMQAKOwsZy04N0CNQU1xwPLy~qh-fNBnYCFjFrYzHvvQc2MR1MJ0tRvvVNdJVlb~dHmzOTFmB8Mxlh5lL~4m1QKWIpljE0E03qVlcxJXEL0L3pCSTKrNIZ~nQy6qSKVgSJJrV5v-c~y0UeDfqQhS9gOSlbBk8uDVIGWo9EqHIyKLAIxDPnwJQ36~Q-WzFQHaBQH1bWmHGQjdFzXb-4lVb0rvk9o8U4N0xUL9jR~0yN1qBj0o2Ip3lAFsPR9v2Jl6nWqfkgmw4RlM~B86BsVrSwcLBMKuaNBKlzBcLqfzqG5BzZg__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA" alt="Diffusion MRI tractography workflow" class="content-image">
                        <p class="image-caption">Structural connectome analysis workflow using diffusion MRI. Source: Brain (Oxford, 2023)</p>
                    </div>
                    <div>
                        <img src="https://thejns.org/view/journals/neurosurg-focus/48/2/article-pE6/article-pE6-fig01.jpg" alt="White matter tractography with tumor" class="content-image">
                        <p class="image-caption">FA color map showing relationship of tumor to white matter tracts. Source: Neurosurgical Focus (2020)</p>
                    </div>
                </div>

                <h4>Methodology</h4>
                <p>Advanced MRI protocols characterize patient brain network architecture:</p>
                <ul>
                    <li><strong>Diffusion MRI tractography:</strong> Probabilistic or deterministic fiber tracking maps structural connectivity and white matter pathways</li>
                    <li><strong>Resting-state functional MRI:</strong> BOLD signal correlations identify functional networks and hub regions</li>
                    <li><strong>Graph-theoretic analysis:</strong> Quantifies network topology, segregation, integration, and resilience</li>
                    <li><strong>Network controllability modeling:</strong> Predicts cascade effects of local disruptions</li>
                </ul>

                <h4>Quantitative Metrics</h4>
                <ul>
                    <li>Hub vulnerability scores (node degree, betweenness centrality)</li>
                    <li>Connectome disruption indices (deviation from age-matched controls)</li>
                    <li>Predicted cognitive impact scores for surgical corridors</li>
                    <li>Radiation field overlap with critical networks</li>
                    <li>Network reorganization capacity (plasticity potential)</li>
                </ul>

                <div class="evidence-box">
                    <h4>Clinical Utility - Key Research Findings</h4>
                    <p><strong>Connectome analysis reveals widespread disruption and predicts outcomes:</strong></p>
                    <ul>
                        <li>Connectome disruptions extend beyond visible tumor margins and correlate with cognitive impairment (P < 0.001)</li>
                        <li>Distant connectome disruption predicts worse overall survival (HR = 1.46, P = 0.049) and progression-free survival (HR = 1.49, P = 0.019)</li>
                        <li>Preserved connectome regions show evidence of network reorganization associated with better outcomes</li>
                        <li>Structural connectivity mapping identifies occult tumor invasion invisible on conventional MRI</li>
                        <li>Functional proximity to tumor predicts network deterioration more accurately than anatomical distance</li>
                    </ul>
                    <p><em>Sources: Brain (Oxford, 2023), The Lancet Neurology (2024), Neuro-Oncology Advances (2024), Scientific Reports (2020)</em></p>
                </div>
            </div>

            <div class="content-section">
                <h3>Integrated Treatment Planning Workflow</h3>
                
                <h4>Phase 1: Pre-treatment Assessment (Weeks 1-6)</h4>
                <ol>
                    <li><strong>Organoid establishment:</strong> Obtain surgical specimen or biopsy; initiate organoid culture (turnaround: 4-6 weeks)</li>
                    <li><strong>Drug panel screening:</strong> Test standard-of-care and targeted agents; generate sensitivity profiles</li>
                    <li><strong>Advanced MRI acquisition:</strong> Perform diffusion MRI (30-dir minimum, multi-shell preferred) and resting-state fMRI (8-10 minutes)</li>
                    <li><strong>Connectome analysis:</strong> Process tractography, generate network maps, calculate vulnerability indices</li>
                </ol>

                <h4>Phase 2: Multidisciplinary Integration (Week 6-7)</h4>
                <ol start="5">
                    <li><strong>Tumor board review:</strong> Neurosurgery, neuro-oncology, radiation oncology, neuroimaging, cognitive neurology</li>
                    <li><strong>Data synthesis:</strong> Cross-reference organoid sensitivity data with connectome risk maps</li>
                    <li><strong>Treatment optimization:</strong> Select surgical approach minimizing hub disruption; design radiation fields sparing vulnerable networks; choose systemic therapy based on organoid response and predicted cognitive impact</li>
                </ol>

                <h4>Phase 3: Treatment Execution & Monitoring (Ongoing)</h4>
                <ol start="8">
                    <li><strong>Baseline cognitive assessment:</strong> Montreal Cognitive Assessment, Hopkins Verbal Learning Test, Trail Making Test</li>
                    <li><strong>Treatment delivery:</strong> Execute optimized plan</li>
                    <li><strong>Longitudinal follow-up:</strong> Serial cognitive testing at 3, 6, and 12 months; repeat connectome imaging to assess network reorganization</li>
                </ol>
            </div>

            <div class="content-section">
                <h3>Implementation Checklist</h3>
                <h4>For Neuro-Oncology Programs:</h4>
                <div style="display: grid; grid-template-columns: 1fr 1fr; gap: 2rem;">
                    <div>
                        <p><strong>Infrastructure:</strong></p>
                        <ul>
                            <li>☐ Organoid facility access (internal or partnership)</li>
                            <li>☐ Advanced MRI protocols (diffusion + rs-fMRI)</li>
                            <li>☐ Computational analysis pipeline</li>
                            <li>☐ Bioinformatics support</li>
                        </ul>
                    </div>
                    <div>
                        <p><strong>Personnel:</strong></p>
                        <ul>
                            <li>☐ Neuroimaging physicist/analyst</li>
                            <li>☐ Stem cell biologist</li>
                            <li>☐ Research coordinator</li>
                            <li>☐ Cognitive neurologist</li>
                        </ul>
                    </div>
                </div>
            </div>

            <div class="evidence-box" style="margin-top: 3rem;">
                <h3>Evidence Snapshot: Recent Publications</h3>
                <p><strong>Supporting research from 2023-2025:</strong></p>
                <ul>
                    <li><strong>Wei et al. (Brain, 2023):</strong> Structural connectome quantifies tumor invasion and predicts survival</li>
                    <li><strong>Friedrich et al. (Neuro-Oncology Advances, 2024):</strong> Connectome-based predictive modeling of cognitive deficits</li>
                    <li><strong>Wang et al. (npj Precision Oncology, 2024):</strong> Multidimensional atlas of GBM organoids reveals drug targets</li>
                    <li><strong>Duffau et al. (The Lancet Neurology, 2024):</strong> Paradigm shift in understanding glioblastoma and brain connectivity</li>
                    <li><strong>Linkous et al. (Cell Reports, 2019):</strong> Patient-derived glioblastoma organoids for precision therapy</li>
                </ul>
            </div>
        </div>
    </section>

    <!-- Implementation Section -->
    <section id="implementation" class="section" style="background: var(--soft-gray-blue);">
        <div class="container">
            <h2 class="section-title">Integrating Organoid–Connectome Workflows in Cancer Centers</h2>
            <p class="section-subtitle">A step-by-step framework for institutional adoption</p>

            <!-- MRI scanner image for clinical setting -->
            <img src="https://images.unsplash.com/photo-1516549655169-df83a0774514?w=900" alt="MRI scanner in clinical setting" class="content-image" style="max-width: 800px; display: block; margin: 3rem auto;">
            <p class="image-caption">Advanced MRI technology enables connectome mapping in clinical settings. Image: Unsplash</p>

            <div class="content-section">
                <h3>Why Institutions Should Adopt This Model</h3>
                <h4>Strategic Value:</h4>
                <ul>
                    <li><strong>Clinical differentiation:</strong> Position your center as a leader in precision neuro-oncology</li>
                    <li><strong>Quality metrics:</strong> Reduce preventable treatment-related cognitive morbidity (current rate: 33%)</li>
                    <li><strong>Patient outcomes:</strong> Improve long-term functional outcomes and quality of life</li>
                    <li><strong>Research productivity:</strong> Generate publishable data and secure competitive grant funding</li>
                    <li><strong>Workforce development:</strong> Attract top faculty and trainees interested in cutting-edge approaches</li>
                </ul>
            </div>

            <div class="content-section">
                <h3>Implementation Roadmap</h3>
                
                <h4>Phase 1: Infrastructure Development (Months 1-3)</h4>
                <ul>
                    <li>☐ Identify organoid-testing capability (internal stem-cell core or external partner like Crown Bioscience, Vivia Biotech)</li>
                    <li>☐ Upgrade MRI protocols: add 30+ direction diffusion sequence, 8-10 minute resting-state fMRI</li>
                    <li>☐ Recruit computational expertise: neuroimaging physicist, network analyst, or collaboration with university partner</li>
                    <li>☐ Secure seed funding: institutional innovation fund, pilot grant, or philanthropic support ($200K-500K typical)</li>
                </ul>

                <h4>Phase 2: Workflow Integration (Months 4-6)</h4>
                <ul>
                    <li>☐ Develop SOPs for tissue procurement, organoid culture, and drug screening</li>
                    <li>☐ Establish connectome analysis pipeline using tools like FSL, MRtrix3, or DSI Studio</li>
                    <li>☐ Train tumor board members through didactic sessions and case reviews</li>
                    <li>☐ Implement cognitive assessment battery (MoCA, HVLT, TMT, COWAT)</li>
                    <li>☐ Create data management system linking organoid results, imaging data, and outcomes</li>
                </ul>

                <h4>Phase 3: Pilot Cohort (Months 7-12)</h4>
                <ul>
                    <li>☐ Enroll 10-20 newly diagnosed GBM patients (power calculation for feasibility study)</li>
                    <li>☐ Collect organoid sensitivity data and connectome maps prospectively</li>
                    <li>☐ Integrate findings into multidisciplinary treatment planning</li>
                    <li>☐ Track cognitive outcomes at 3, 6, and 12 months</li>
                    <li>☐ Monitor feasibility metrics: completion rate, turnaround time, clinical impact</li>
                </ul>

                <h4>Phase 4: Program Expansion & Dissemination (Months 12+)</h4>
                <ul>
                    <li>☐ Analyze pilot data: cognitive outcome differences, survival trends, cost-benefit</li>
                    <li>☐ Publish results in peer-reviewed journals (target: Neuro-Oncology, JCO, JAMA Oncology)</li>
                    <li>☐ Present at national meetings (SNO, ASCO, ASTRO)</li>
                    <li>☐ Expand to full clinical integration</li>
                    <li>☐ Pursue R01/U01 funding for multi-center validation</li>
                    <li>☐ Develop training program for other institutions</li>
                </ul>
            </div>

            <div class="content-section">
                <h3>Required Infrastructure</h3>
                
                <div style="display: grid; grid-template-columns: 1fr 1fr; gap: 3rem; margin-top: 2rem;">
                    <div>
                        <h4>Organoid Profiling:</h4>
                        <ul>
                            <li>Biosafety Level 2 laboratory space</li>
                            <li>Cell culture equipment (incubators, biosafety cabinets)</li>
                            <li>Microscopy (brightfield, fluorescence)</li>
                            <li>Viability assay instrumentation</li>
                            <li>Biobanking capability (liquid nitrogen storage)</li>
                            <li>Personnel: 1-2 FTE technicians/scientists</li>
                        </ul>
                    </div>
                    <div>
                        <h4>Connectome Mapping:</h4>
                        <ul>
                            <li>3T MRI scanner (Siemens, GE, Philips)</li>
                            <li>Diffusion-capable gradients (≥40 mT/m)</li>
                            <li>Computational cluster or workstation</li>
                            <li>Analysis software (FSL, MRtrix3, FreeSurfer)</li>
                            <li>Visualization tools (Connectome Workbench, 3D Slicer)</li>
                            <li>Personnel: 0.5-1 FTE imaging physicist/analyst</li>
                        </ul>
                    </div>
                </div>
            </div>

            <div class="content-section">
                <h3>Policy Recommendations</h3>
                
                <h4>Institutional Level:</h4>
                <ul>
                    <li>Mandate organoid profiling for all eligible newly diagnosed GBM cases</li>
                    <li>Include advanced connectome imaging in standard pre-surgical MRI bundles</li>
                    <li>Establish cognitive outcomes as tracked quality metric (analogous to surgical complications)</li>
                    <li>Create protected time for cognition-focused tumor board sessions</li>
                </ul>

                <h4>Payer & Regulatory Level:</h4>
                <ul>
                    <li>Advocate for CPT codes specific to organoid drug-response testing</li>
                    <li>Pursue coverage for advanced connectome MRI under precision oncology indications</li>
                    <li>Support NIH BRAIN Initiative expansion to neuro-oncology applications</li>
                    <li>Engage FDA in regulatory pathways for organoid-guided therapy selection</li>
                </ul>
            </div>

            <div class="evidence-box">
                <h3>Benefits of Adoption</h3>
                <ul>
                    <li><strong>Patient care:</strong> Reduces avoidable treatment-related cognitive decline</li>
                    <li><strong>Precision medicine:</strong> Improves therapy selection accuracy</li>
                    <li><strong>Quality of life:</strong> Enhances long-term functional outcomes without sacrificing tumor control</li>
                    <li><strong>Institutional reputation:</strong> Establishes center as leader in next-generation neuro-oncology</li>
                    <li><strong>Health equity:</strong> Extends personalized medicine to underserved populations</li>
                    <li><strong>Research impact:</strong> Generates high-value publications and competitive grant proposals</li>
                </ul>
            </div>
        </div>
    </section>

    <!-- Resources Section -->
    <section id="resources" class="section">
        <div class="container">
            <h2 class="section-title">Additional Resources</h2>

            <div class="three-column">
                <div class="column">
                    <h3>For Patients & Families</h3>
                    <h4>National Brain Tumor Society (NBTS)</h4>
                    <p>Patient education, clinical trial finder, support resources, and advocacy.</p>
                    <a href="https://braintumor.org" style="color: var(--slate-blue);">braintumor.org →</a>
                    
                    <h4 style="margin-top: 2rem;">American Brain Tumor Association (ABTA)</h4>
                    <p>CareLine support, publications, local support groups, and educational resources.</p>
                    <a href="https://abta.org" style="color: var(--slate-blue);">abta.org →</a>

                    <h4 style="margin-top: 2rem;">National Cancer Institute</h4>
                    <p>Comprehensive information on brain tumors, treatment, and clinical trials.</p>
                    <a href="https://www.cancer.gov/types/brain" style="color: var(--slate-blue);">cancer.gov/types/brain →</a>
                </div>

                <div class="column">
                    <h3>For Clinicians</h3>
                    <h4>Society for Neuro-Oncology (SNO)</h4>
                    <p>Clinical guidelines, research updates, annual meeting, and professional networking.</p>
                    <a href="https://soc-neuro-onc.org" style="color: var(--slate-blue);">soc-neuro-onc.org →</a>
                    
                    <h4 style="margin-top: 2rem;">NIH BRAIN Initiative</h4>
                    <p>Funding opportunities and research networks advancing brain connectivity mapping.</p>
                    <a href="https://braininitiative.nih.gov" style="color: var(--slate-blue);">braininitiative.nih.gov →</a>

                    <h4 style="margin-top: 2rem;">Human Connectome Project</h4>
                    <p>Open-access data, analysis tools, and protocols for connectome research.</p>
                    <a href="https://www.humanconnectome.org" style="color: var(--slate-blue);">humanconnectome.org →</a>
                </div>

                <div class="column">
                    <h3>Key Terms Glossary</h3>
                    <p><strong>Organoid:</strong> Three-dimensional tissue culture derived from stem cells that mimics organ structure and function.</p>
                    <p style="margin-top: 1rem;"><strong>Connectome:</strong> Comprehensive map of neural connections within the brain, visualized using diffusion and functional MRI.</p>
                    <p style="margin-top: 1rem;"><strong>Diffusion MRI:</strong> Imaging technique tracking water molecule movement to map white matter pathways.</p>
                    <p style="margin-top: 1rem;"><strong>Hub Vulnerability:</strong> Degree to which highly connected brain regions are susceptible to treatment damage.</p>
                    <p style="margin-top: 1rem;"><strong>MGMT Methylation:</strong> Molecular marker predicting temozolomide chemotherapy response.</p>
                </div>
            </div>
        </div>
    </section>

    <!-- Contact Section -->
    <section id="contact" class="section" style="background: var(--soft-gray-blue);">
        <div class="container">
            <h2 class="section-title">Get Involved</h2>
            <p class="section-subtitle">Whether you're a patient, clinician, or researcher, there's a role for you in advancing cognition-preserving neuro-oncology.</p>

            <div class="three-column">
                <div class="column">
                    <h3>For Patients & Families</h3>
                    <p><strong>Advocate for better care:</strong></p>
                    <ul style="margin-left: 1rem;">
                        <li>Share this website with your neuro-oncology team</li>
                        <li>Request referral to centers piloting these approaches</li>
                        <li>Ask whether treatment planning can incorporate cognitive-risk assessment</li>
                        <li>Connect with advocacy organizations</li>
                    </ul>
                </div>

                <div class="column">
                    <h3>For Clinicians & Researchers</h3>
                    <p><strong>Launch an integrated program:</strong></p>
                    <ul style="margin-left: 1rem;">
                        <li>Access implementation guidance and protocols</li>
                        <li>Connect with organoid-testing facilities</li>
                        <li>Obtain computational analysis support</li>
                        <li>Join multi-center research networks</li>
                        <li>Access grant writing resources</li>
                    </ul>
                </div>

                <div class="column">
                    <h3>For Hospitals & Cancer Centers</h3>
                    <p><strong>Become an early adopter:</strong></p>
                    <ul style="margin-left: 1rem;">
                        <li>Pilot program design and support</li>
                        <li>Staff training and education</li>
                        <li>IRB protocol templates</li>
                        <li>Data collection strategies</li>
                        <li>Publication planning</li>
                    </ul>
                </div>
            </div>

            <div style="text-align: center; margin-top: 5rem;">
                <h3 style="color: var(--charcoal); margin-bottom: 2rem;">Join the Movement</h3>
                <p style="font-size: 1.2rem; max-width: 700px; margin: 0 auto;">Cognition-preserving neuro-oncology is not a distant future—it's happening now at leading institutions worldwide. Be part of the shift toward truly personalized brain tumor care.</p>
            </div>
        </div>
    </section>

    <!-- Footer -->
    <footer>
        <div class="footer-content">
            <div class="footer-section">
                <h4>From Cells to Circuits</h4>
                <p>A public health education initiative focused on advancing precision neuro-oncology through integration of organoid drug-response profiling and connectome-based vulnerability mapping.</p>
            </div>
            <div class="footer-section">
                <h4>Navigation</h4>
                <a href="#home">Home</a>
                <a href="#patients">For Patients</a>
                <a href="#clinicians">For Clinicians</a>
                <a href="#implementation">Implementation</a>
                <a href="#resources">Resources</a>
                <a href="#contact">Contact</a>
            </div>
            <div class="footer-section">
                <h4>Evidence-Based Content</h4>
                <p>All content supported by peer-reviewed research from leading institutions and journals (2019-2025).</p>
            </div>
        </div>

        <!-- Image & Research References -->
        <div class="references-section">
            <h4>Image & Research Sources</h4>
            <p><strong>Research Images:</strong></p>
            <p>• Linkous, A. et al. (2019). Modeling Patient-Derived Glioblastoma with Cerebral Organoids. Cell Reports 26(12), 3203-3211. Available: https://www.cell.com/cell-reports/fulltext/S2211-1247(19)30242-6</p>
            <p>• Wei, W. et al. (2023). Structural connectome quantifies tumour invasion and predicts survival in glioblastoma patients. Brain 146(4), 1714-1727. Available: https://academic.oup.com/brain/article/146/4/1714/6746935</p>
            <p>• Gopalakrishnan, J. et al. (2020). Trends and challenges in modeling glioma using 3D human brain organoids. Cell Death & Differentiation 28, 15-23. Available: https://www.nature.com/articles/s41418-020-00679-7</p>
            <p>• Endersby, R. & Hankinson, T.C. (2020). Tractography and the connectome in neurosurgical treatment of gliomas. Neurosurgical Focus 48(2), E6. Available: https://thejns.org/focus/view/journals/neurosurg-focus/48/2/article-pE6.xml</p>
            
            <p style="margin-top: 1rem;"><strong>Stock Medical Images:</strong></p>
            <p>• Unsplash (Creative Commons Zero): https://unsplash.com - Brain and medical imagery by Robina Weermeijer, National Cancer Institute, and other contributors</p>
            
            <p style="margin-top: 1rem;"><strong>Key Scientific Publications Cited:</strong></p>
            <p>• Wang, C. et al. (2024). A multidimensional atlas of human glioblastoma-like organoids. npj Precision Oncology 8, 19</p>
            <p>• Duffau, H. et al. (2024). Glioblastoma and brain connectivity: the need for a paradigm shift. The Lancet Neurology 23(7), 740-753</p>
            <p>• Friedrich, M. et al. (2024). Structural connectome-based predictive modeling of cognitive deficits in treated glioma patients. Neuro-Oncology Advances 6(1), vdad151</p>
            <p>• Multiple publications from Nature Communications, PMC, Oxford Academic, Scientific Reports (2020-2025)</p>
        </div>

        <div class="footer-bottom">
            <p>© 2025 From Cells to Circuits. Educational resource based on peer-reviewed research. This website provides educational information and should not replace professional medical advice. Always consult qualified healthcare providers for medical decisions.</p>
        </div>
    </footer>

    <script>
        // Smooth scrolling
        document.querySelectorAll('a[href^="#"]').forEach(anchor => {
            anchor.addEventListener('click', function (e) {
                e.preventDefault();
                const target = document.querySelector(this.getAttribute('href'));
                if (target) {
                    const navHeight = document.querySelector('nav').offsetHeight;
                    const targetPosition = target.offsetTop - navHeight;
                    window.scrollTo({
                        top: targetPosition,
                        behavior: 'smooth'
                    });
                }
            });
        });

        // Active navigation state
        window.addEventListener('scroll', () => {
            let current = '';
            const sections = document.querySelectorAll('section');
            
            sections.forEach(section => {
                const sectionTop = section.offsetTop;
                if (pageYOffset >= sectionTop - 100) {
                    current = section.getAttribute('id');
                }
            });

            document.querySelectorAll('.nav-links a').forEach(link => {
                link.classList.remove('active');
                if (link.getAttribute('href').slice(1) === current) {
                    link.classList.add('active');
                }
            });
        });
    </script>
</body>
</html>
